Clinical Research Directory
Browse clinical research sites, groups, and studies.
Resveratrol for Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes
Sponsor: Universitas Sriwijaya
Summary
Type 2 diabetes mellitus is associated with endothelial dysfunction, which contributes to increased cardiovascular risk. Chronic hyperglycemia induces oxidative stress and reduces nitric oxide bioavailability, leading to impaired endothelial function. Resveratrol, a natural polyphenol with antioxidant and anti-inflammatory properties, has been shown to improve endothelial function in experimental studies. This randomized controlled trial aims to evaluate the effectiveness of resveratrol supplementation in improving endothelial dysfunction and metabolic control in patients with type 2 diabetes mellitus. Endothelial function will be assessed using flow-mediated dilatation (FMD) of the brachial artery and serum endothelial nitric oxide synthase (eNOS) levels. Metabolic parameters including fasting blood glucose, postprandial glucose, HbA1c, and lipid profile will also be evaluated.
Official title: Effectiveness of Resveratrol Addition in Improving Endothelial Dysfunction and Metabolic Control in Type 2 Diabetes Mellitus Patients: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-05
Completion Date
2026-10
Last Updated
2026-05-06
Healthy Volunteers
No
Interventions
Resveratrol
Resveratrol 50 mg administered orally once daily for 12 weeks.
Placebo
Matching placebo administered orally once daily for 12 weeks.
Locations (1)
Universitas Sriwijaya
Palembang, South Sumatera, Indonesia